Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
Go back to Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.82 -1.27 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.09 | 52 Week High | $77.12 | |||
| Open | $67.24 | 52 Week Low | $49.03 | |||
| Day High | $67.72 | P/E | 43.39 | |||
| Day Low | $66.58 | EPS | $1.54 | |||
| Volume | 4,825,368 | |||||
